European Marketing Authorization Holder (MAH)

Your Trusted MAH Partner in Europe

A Marketing Authorization Holder (MAH) is the legal entity responsible for obtaining and maintaining the authorization to market a medicinal product across Europe. The MAH ensures compliance with EU/UK regulations, including Good Manufacturing Practices (GMP), pharmacovigilance obligations, supply chain oversight, and quality control. The responsibility for the performance of a medicinal product over its lifetime, its safety, quality and efficacy, lies with the MAH. For pharmaceutical companies without an EU or UK presence, securing an experienced MAH partner is critical to regulatory success.

Speak with an Expert

Why Choose ProPharma?

With over 20 years of experience in commercializing medicinal products, ProPharma has successfully supported pharmaceutical companies worldwide in achieving marketing authorization, achieving reimbursement, and maintaining compliance. We provide:

A trusted partner for all MAH responsibilities, including acting as your MAH

Expert guidance tailored to your specific regulatory and market access needs

Comprehensive support from regulatory submissions to post-market compliance
Proven success in navigating country-specific pricing and reimbursement challenges
EU and UK MIA licenses and WDA support

Partner with ProPharma to simplify your market entry across Europe and ensure long-term compliance. Contact us today to learn more about how we can support your marketing authorization needs.

Speak with an Expert

professionals-pointing-to-laptop-as-914178358

ProPharma's Comprehensive MAH Services

Navigating both the specific country and centralized European regulations and requirements to supply medicinal products to the European markets can be a complex challenge.

With decades of experience, our experts provide a full spectrum of MAH services to support pharmaceutical companies in successfully navigating the regulatory requirements across Europe. Our tailored solutions ensure compliance, streamline market entry, and maintain product integrity.

Regulatory & Compliance Support

Guidance on selecting the optimal regulatory pathway
Full gap analysis, MAA readiness assessment and pre-submission activity support
End-to-end regulatory submissions for marketing authorization applications (Centralized, Decentralized, Mutual Recognition, and National Procedures)
Maintenance of marketing authorizations, including variations and renewals
Dossier preparation and procedural management
Lifecycle management

Pharmacovigilance & Safety Management

PV gap analysis to ensure inspection readiness
Full pharmacovigilance system implementation, including QPPV services
Development and maintenance of the Pharmacovigilance System Master File (PSMF)
Signal detection, case processing and submission, literature search, and risk management planning
Compliance with Good Pharmacovigilance Practices (GVP) requirements
Provision of Local responsible Person for Pharmacovigilance (LPPV), as applicable

Quality & Manufacturing Oversight

EEA/UK GMP compliance support, including Qualified Person (QP) and Responsible Person (RP) services
Batch release and supply chain oversight for seamless product distribution
Manufacturing license (MIA) support and QP declarations
Labelling, packaging, and serialization compliance with EEA/UK standards

Market Access & Commercialization

Strategic support for pricing and reimbursement
Joint Clinical Assessment (JCA) dossier preparation and submission
National Health Technology Assessment (HTA) dossier preparations and submissions
Guidance on selecting the optimal market entry
Competitive landscape analysis and product positioning
Price and reimbursement maintenance, including renewals

Tailored Solutions for Specific Challenges

Pharmaceutical companies—whether generic or biosimilar manufacturers, orphan drug or ATMP (cell and gene) manufacturers, non-EU companies or innovative drug developers—face unique challenges in obtaining EU marketing authorization. We offer specialized solutions to address these hurdles.

Challenges Faced by Non-European Companies & ProPharma Solutions

ProPharma offers comprehensive support by guiding companies through regulatory pathways, conducting gap analyses, facilitating regulatory meetings, ensuring quality compliance, and providing QPPV services. With expertise in pricing strategies and logistics, ProPharma streamlines the EU market entry process for US companies, ensuring regulatory success and commercial viability.

Challenge: Understanding EMA requirements vs. FDA and/or other regional regulations.

Solution: ProPharma provides expert guidance on EEA/UK regulatory frameworks.

Challenge: Adapting US-based clinical data to meet EEA/UK standards.

Solution: ProPharma conducts gap analyses and supports data generation.

Challenge: Engaging effectively with EMA and national authorities.

Solution: ProPharma facilitates pre-submission meetings and regulatory discussions.

Challenge: Aligning with EEA/UK GMP, GDP, and GVP requirements.

Solution: ProPharma assists in quality system implementation and compliance.

Challenge: Setting up a compliant EEA/UK pharmacovigilance system in more than 30 countries.

Solution: ProPharma offers full pharmacovigilance services, including QPPV and LPPV appointment tailored to our clients needs.

Challenge: Navigating European JCA requirements and complex country-specific HTA and reimbursement processes.

Solution: ProPharma prepares JCA dossier for submission on a European level and develops country-specific pricing and reimbursement dossiers for submission.

Challenge: Establishing an efficient and compliant supply chain.

Solution: ProPharma provides MIA and QP declaration support.

Challenges Faced by Generic or Biosimilar Development Companies & ProPharma Solutions

ProPharma provides tailored solutions by offering expert guidance on bioequivalence studies, dossier compliance, and regulatory submissions, as well as comprehensive support for GMP implementation, QPPV services, and pricing strategies. By streamlining the authorization process, ProPharma enables generic and biosimilar development companies to efficiently enter and succeed in the European market.

Challenge: Proving bioequivalence to the Reference Medicinal Product (RMP) requires well-designed studies and robust data analysis.

Solution: ProPharma advises on study design, conducts rigorous data analysis, and ensures EMA compliance for successful bioequivalence demonstration.

Challenge: Selecting the optimal approval pathway can be complex.

Solution: ProPharma provides strategic guidance and application management centralized and across multiple EU member states.

Challenge: Adapting existing data to meet EU regulatory standards.

Solution: ProPharma ensures dossier compliance, including API characterization and stability studies.

Challenge: Variations or withdrawals of the RMP affecting generic approvals.

Solution: ProPharma actively monitors RMP changes and advises on regulatory updates.

Challenge: Ensuring compliance with EEA/UK GMP standards.

Solution: ProPharma supports GMP implementation and quality assurance.

Challenge: Maintaining a compliant pharmacovigilance system.

Solution: ProPharma offers full pharmacovigilance support, including QPPV services and risk management.

Challenge: Navigating country-specific aggressive generic drug price controls and pricing regulations.

Solution: ProPharma provides full competitive pricing analysis followed by reimbursement preparation and submission with price maintenance support.

News & Insights

Thought Leadership Webinars Press Awards Resource Library

November 6, 2025

Reclaiming the European Market: How to Secure EU/UK MAH Status Without the Local...

Discover how non-European pharma companies can quickly and compliantly secure EU/UK Marketing Authorisation Holder status without local infrastructure, ensuring market success.

Read Full Article

October 28, 2025

FDA Tightens the Reins on DTC Drug Ads: Big Picture Insights and Industry Implic...

FDA issues 61 enforcement letters targeting deceptive drug advertising. Explore key trends, efficacy violations, and CCN compliance insights.

Read Full Article

October 23, 2025

How Mature Are Your Data Integrity Practices? New FDA and EU Regulatory Focus A...

Explore the evolving regulatory landscape in data integrity with FDA and EU 2025 updates, focusing on digital systems, AI, and stringent compliance measures.

Read Full Article

View all Thought Leadership

July 8, 2025

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice Presid...

ProPharma appoints former FDA labeling expert as VP, Labeling & Strategy, enhancing strategic labeling, promotional review, and regulatory consulting expertise to accelerate drug development and...

Read Full Article

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

Read Full Article

October 21, 2024

ProPharma Appoints Brian Tuttle as Chief Financial Officer

ProPharma appoints Brian Tuttle as CFO to drive financial strategy and accelerate global growth, leveraging his 20 years of life sciences industry experience.

Read Full Article

View all Press

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

Read Full Article

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

Read Full Article

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Read Full Article

View all Awards

Article

November 7, 2025

Tariff Tensions: How Pharma Can Prepare for Supply Chain & Cost Disruption

U.S. tariff policies are shifting fast and pharma companies dependent on global supply chains are feeling the strain. With new tariffs on APIs, excipients, and finished drug products climbing as high...

Read Full Article

Article

November 5, 2025

The Relevance of AI in Medical Information: Transforming Communication, Complian...

Artificial intelligence (AI) is no longer a future concept — it’s transforming Medical Information (MI) today. In a field where accuracy, empathy, and speed define trust, AI is emerging not just as a...

Read Full Article

Article

October 30, 2025

Improving Patient Health and Safety through Pharmacovigilance and Medical Inform...

In today’s data-driven pharmaceutical landscape, patient safety depends on more than vigilance — it demands collaboration. Pharmacovigilance and Medical Information teams are no longer operating in...

Read Full Article

View all Resources

November 18, 2025

Navigating the New EU HTA Regulation as an MAH: Strategic Insights for Successful JCA Submissions

Explore how the new EU HTA Regulation (EU HTAR) is transforming market access across Europe. Join our expert to learn practical strategies for successful Joint Clinical Assessment (JCA) submissions,...

November 11, 2025

Tips for Successful MAA Submissions in Europe

Navigate the complexities of EU marketing authorization to explore tips for successful Marketing Authorization Application (MAA) submissions in Europe to ensure proven strategies, reduced delays, and...

October 16, 2025

AI in Medical Information: Who Holds the Responsibility?

In Medical Information (MI) and beyond, key questions arise: Who ensures accuracy, compliance, and ethical use — individual contributors, leadership, pharma clients, or technology providers? And what...

Watch the Replay

View all Webinars

News & Insights

November 6, 2025

Reclaiming the European Market: How to Secure EU/UK MAH Status Without the Local...

Discover how non-European pharma companies can quickly and compliantly secure EU/UK Marketing Authorisation Holder status without local infrastructure, ensuring market success.

Read This Article

October 28, 2025

FDA Tightens the Reins on DTC Drug Ads: Big Picture Insights and Industry Implic...

FDA issues 61 enforcement letters targeting deceptive drug advertising. Explore key trends, efficacy violations, and CCN compliance insights.

Read This Article

October 23, 2025

How Mature Are Your Data Integrity Practices? New FDA and EU Regulatory Focus A...

Explore the evolving regulatory landscape in data integrity with FDA and EU 2025 updates, focusing on digital systems, AI, and stringent compliance measures.

Read This Article

July 8, 2025

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice Presid...

ProPharma appoints former FDA labeling expert as VP, Labeling & Strategy, enhancing strategic labeling, promotional review, and regulatory consulting expertise to accelerate drug development and...

Read This Article

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

Read This Article

October 21, 2024

ProPharma Appoints Brian Tuttle as Chief Financial Officer

ProPharma appoints Brian Tuttle as CFO to drive financial strategy and accelerate global growth, leveraging his 20 years of life sciences industry experience.

Read This Article

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

Read This Article

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

Read This Article

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Read This Article

Article

November 7, 2025

Tariff Tensions: How Pharma Can Prepare for Supply Chain & Cost Disruption

View This Resource

Article

November 5, 2025

The Relevance of AI in Medical Information: Transforming Communication, Complian...

View This Resource

Article

October 30, 2025

Improving Patient Health and Safety through Pharmacovigilance and Medical Inform...

View This Resource

November 18, 2025

Navigating the New EU HTA Regulation as an MAH: Strategic Insights for Successful JCA Submissions

November 11, 2025

Tips for Successful MAA Submissions in Europe

October 16, 2025

AI in Medical Information: Who Holds the Responsibility?

Watch the Replay